MediciNova (NASDAQ:MNOV) Posts Earnings Results

Posted by Geri Gentry on May 15th, 2026

MediciNova (NASDAQ:MNOV – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01, FiscalAI reports. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.13 million.

MediciNova Price Performance

MNOV stock opened at $1.40 on Friday. MediciNova has a 52-week low of $1.17 and a 52-week high of $1.96. The company’s 50 day simple moving average is $1.41 and its 200-day simple moving average is $1.46. The firm has a market capitalization of $68.91 million, a P/E ratio of -5.83 and a beta of 0.63.

Analyst Upgrades and Downgrades

MNOV has been the topic of a number of research reports. Zacks Research upgraded shares of MediciNova to a “hold” rating in a report on Tuesday, March 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediciNova in a report on Friday, March 27th. Maxim Group reiterated a “buy” rating and issued a $6.00 target price on shares of MediciNova in a report on Monday, March 23rd. HC Wainwright initiated coverage on shares of MediciNova in a report on Monday, March 16th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of MediciNova in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Read Our Latest Research Report on MNOV

Institutional Investors Weigh In On MediciNova

A number of large investors have recently made changes to their positions in MNOV. Citadel Advisors LLC acquired a new stake in shares of MediciNova during the third quarter valued at approximately $92,000. Goldman Sachs Group Inc. acquired a new stake in shares of MediciNova during the fourth quarter valued at approximately $35,000. StoneX Group Inc. acquired a new stake in shares of MediciNova during the fourth quarter valued at approximately $25,000. Jane Street Group LLC acquired a new stake in shares of MediciNova during the fourth quarter valued at approximately $214,000. Finally, State Street Corp raised its holdings in shares of MediciNova by 10.9% during the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after acquiring an additional 19,100 shares during the period. Institutional investors and hedge funds own 9.90% of the company’s stock.

MediciNova Company Profile

(Get Free Report)

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.